Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

December 2024

Anatomic pathology selected abstracts

December 2024—Recurrence of Crohn’s disease within one or two years of resection is common. The authors conducted a study in which they sought to identify histologic features in Crohn’s disease resections that may predict earlier recurrence (18 months or less) to potentially guide postoperative management. They performed a single-institution, retrospective database review of 41 patients who had first-time Crohn’s disease bowel resection specimens collected between October 2002 and December 2007. Patient demographics and Crohn’s disease course were documented. Slides were reviewed for the distribution and composition of inflammation, small bowel pyloric metaplasia, and the presence and characteristics of submucosal fibrosis and granulomas.

Molecular pathology selected abstracts

December 2024—Acute promyelocytic leukemia is generally characterized by presence of the PML::RARA fusion. However, a subset of cases with morphological, cytochemical, and immunophenotypic features of acute promyelocytic leukemia (APL) lack this canonical fusion gene and instead present with alternate fusions. These include RARA fusions with partners other than PML and fusions involving other retinoic acid receptor (RAR) genes, such as RARG. Leukemias with these variant fusions often resist all-trans retinoic acid (ATRA) therapy. Specifically, the ATRA sensitivity of RARA fusion genes varies based on its 5′ fusion partner. Interestingly, in some studies, the artificially induced variant RAR bipartite fusion genes responded well to ATRA.

Newsbytes

December 2024—In a casual water cooler conversation, while standing around a coagulation analyzer to be precise, Lisa Daniel listened to her laboratory colleagues and a hospitalist, who happened to stop by the department, discuss their frustration with duplicate and other unnecessary tests. This led her to start a small committee, which in eight years has sextupled in size and undertaken numerous cost-saving measures.

Q&A column

December 2024
Q. What are the preferred tests for chronic kidney disease (CKD) screening and classification? Read answer.
Q. Is there a formula to correct a white blood cell count for micromegakaryocytes, or are megakaryocytes considered clinically insignificant unless there are greater than five per 100 WBCs? Is there a movement to drop reporting percents for individual WBCs, reactive lymphocytes, and reticulocytes? If so, does the CAP support such a change? Read answer.

Put It on the Board

December 2024—In a white paper released this fall, the CAP sets forth five recommendations to address private health insurers’ interference in patient-physician and physician-physician relationships by limiting the number of in-network physicians or exclusively contracting with particular providers and facilities. In the paper, “Examining the State of Health Care’s Private Payers and the Adverse Impact of Insurance Interference,” the CAP says “Two-thirds of the country’s population is covered by private health insurance, yet the coverage provided is less and less meaningful.”

MARKETPLACE

TRENDING